Lofexidine Shortage: What Providers and Prescribers Need to Know in 2026

For addiction medicine specialists, psychiatrists, and primary care providers managing patients through opioid withdrawal, lofexidine (Lucemyra) access issues in 2026 present a real clinical challenge. While lofexidine is not on the FDA's official Drug Shortage list, its sporadic pharmacy availability means patients often struggle to fill prescriptions in a timely manner — and timing is critical during withdrawal. This guide gives providers the information they need to navigate lofexidine access and support patients effectively.

Lofexidine's Current Regulatory and Supply Status

Lofexidine was FDA-approved in May 2018 as the first and only non-opioid, non-scheduled medication approved specifically for the mitigation of opioid withdrawal symptoms in adults. As of 2026, it remains off the FDA Drug Shortages Database, but clinicians should be aware of several factors affecting real-world access:

Manufacturer transition (2025): BioCorRx Pharmaceuticals acquired Lucemyra from USWM LLC in March 2025. Distribution relationships and formulary agreements may still be stabilizing.

Limited routine pharmacy stocking: Due to low prescription volume and high per-unit cost, most general retail pharmacies do not stock lofexidine on their shelves.

Generic lofexidine available: Generic 0.18 mg tablets are available, which expands manufacturing options but does not resolve pharmacy stocking issues.

Clinical Pharmacology Reminders for Prescribers

For providers who prescribe lofexidine less frequently, a brief pharmacology review:

Mechanism: Central alpha-2 adrenergic agonist. Reduces norepinephrine release from adrenergic neurons in the locus coeruleus, attenuating the sympathetic hyperactivity driving opioid withdrawal symptoms.

Dosing: Starting dose: 3 x 0.18 mg tablets QID (5-6 hours apart) during peak withdrawal. Max 4 tablets/dose; max 16 tablets/day (2.88 mg). Duration up to 14 days.

Tapering: Must be tapered over 2-4 days (reduce by 1 tablet/dose every 1-2 days) to avoid rebound hypertension.

Key interactions: Additive QT prolongation with methadone; excess CNS depression with benzodiazepines/barbiturates; elevated lofexidine levels with CYP2D6 inhibitors like paroxetine.

ECG monitoring: Indicated for patients with CHF, bradyarrhythmias, hepatic/renal impairment, or concurrent methadone use.

Not for OUD maintenance: Lofexidine mitigates withdrawal symptoms but is not approved as a treatment for opioid use disorder and should not be prescribed as long-term maintenance therapy.

Insurance and Prior Authorization Challenges

Many commercial insurance plans and Medicaid programs require prior authorization for lofexidine. Prior auth criteria often require documented failure or contraindication to buprenorphine or other preferred withdrawal agents. As the manufacturer transition continues to stabilize formulary placement, some plans may be in the process of updating their lofexidine coverage tiers.

For uninsured patients, the GoodRx coupon price is approximately $383 for a standard supply, and patient assistance services like Prescription Hope offer access for approximately $70/month. Providers should be aware of these options to counsel patients proactively.

Clinical Alternatives When Lofexidine Is Unavailable

When lofexidine cannot be obtained in a timely manner, consider these evidence-based alternatives:

Clonidine (off-label): Same mechanism, broadly available at ~$9/month, well-supported by literature. Monitor BP closely. NICE guidelines specifically note lofexidine as preferred over clonidine, but clonidine remains appropriate when lofexidine is inaccessible.

Buprenorphine: More effective than lofexidine for withdrawal symptom relief and addresses cravings. Preferred for patients with OUD who want long-term maintenance. Initiate 12-24 hours after last short-acting opioid use.

Adjunctive symptom-targeted medications: Ondansetron (nausea), loperamide (diarrhea), hydroxyzine or trazodone (insomnia/anxiety), NSAIDs (aches). These can supplement any primary withdrawal strategy.

When Lofexidine Is the Right Choice

The ASAM 2020 guidelines note that lofexidine may be considered for withdrawal management in certain settings — particularly for patients who prefer a non-opioid approach and wish to transition to extended-release naltrexone (Vivitrol). Since naltrexone requires 7-10 days of opioid abstinence prior to initiation, a non-opioid withdrawal management agent like lofexidine is particularly valuable in this bridge scenario.

How medfinder Supports Your Patients' Access

Refer patients to medfinder for providers as a resource to help them locate lofexidine at a pharmacy near them. medfinder calls pharmacies on behalf of patients, checks current stock, and texts results — eliminating the logistics burden from an already vulnerable patient population. When your patient's recovery timeline is narrow, helping them locate medication quickly can be the difference between starting treatment and relapsing.

For a practical workflow guide, see our post: How to help your patients find lofexidine in stock: A provider's guide.